Treatment of Other Nontuberculous Mycobacteria

Nontuberculous mycobacteria (NTM) are numerous, and for the vast majority of them, randomized studies are lacking and data regarding optimal treatment are limited. When complex (MAC) and are excluded, the main NTM are , and . Treatment is long (at least 12 months after culture conversion according t...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Seminars in respiratory and critical care medicine Ročník 39; číslo 3; s. 377
Hlavní autori:	Basille, Damien, Jounieaux, Vincent, Andréjak, Claire
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.06.2018
Predmet:	Antitubercular Agents - therapeutic use Humans Microbial Sensitivity Tests Mycobacterium Infections, Nontuberculous - drug therapy Mycobacterium Infections, Nontuberculous - epidemiology Mycobacterium Infections, Nontuberculous - microbiology Nontuberculous Mycobacteria - classification Nontuberculous Mycobacteria - drug effects Practice Guidelines as Topic Randomized Controlled Trials as Topic
ISSN:	1098-9048, 1098-9048
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Nontuberculous mycobacteria (NTM) are numerous, and for the vast majority of them, randomized studies are lacking and data regarding optimal treatment are limited. When complex (MAC) and are excluded, the main NTM are , and . Treatment is long (at least 12 months after culture conversion according to recommendations by scientific societies) and difficult (at least three drugs are required, each of which have potential adverse events). Moreover, optimal treatment is unknown for the vast majority of NTM and efficacy of treatment is not 100%. That is why, balance between benefit and risk is fundamental. For , the second most common NTM isolated in Europe, treatment is classically based on macrolides or fluoroquinolones, associated with ethambutol and rifampicin. For , the cornerstone of treatment is rifampicin, which should be associated with two other drugs: ethambutol plus isoniazid or clarithromycin. , which is common in Northern Europe, can be treated by rifampicin, ethambutol, and clarithromycin and/or fluoroquinolones.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1098-9048 1098-9048
DOI:	10.1055/s-0038-1660473